



30 April 2010

ASX/ MEDIA RELEASE

**US Grant Awarded To Support Standard Of Care Using
ImpediMed L-Dex® Testing**

**Headline: Komen Grant Awarded For Evidence-Based Study To Support Standard
Of Care For Lymphoedema Pre-Emptive Care Using L-Dex® Testing**

ImpediMed Limited today announced that US based organization, Susan G. Komen for the Cure®, the world's largest breast cancer advocacy group, has awarded a grant to Dr. Steven Schonholz for use in providing L-Dex® screening for breast cancer patients, within the State of Massachusetts. Dr. Schonholz is the Medical Director of the Mercy Breast Care Center located in Springfield, Massachusetts and was the first US surgeon to incorporate ImpediMed's L-Dex® technology into the routine care of his breast cancer patients.

The grant will be used to fund Dr. Schonholz's study entitled, "Prospective Assessment and Management of Upper Extremity Lymphoedema in Recently-Diagnosed Breast Cancer Patients as the Evidence-Based Standard of Care." The Breast Care Center at the Mercy Hospital will provide education and free prospective L-Dex lymphoedema screening for 250 breast cancer patients in Greater Springfield. They will collaborate with other hospitals as well as ethnic and minority groups to advance prospective lymphoedema screening for all breast cancer survivors.

Commenting on the grant, Dr. Schonholz said, "A fairly high percentage of breast cancer survivors develop lymphoedema as a result of the primary treatment of their cancer. Lymphoedema is a chronic physical impairment that can impact functions in the home and at work, and creates a number of secondary issues related to cosmetics and the quality of life for breast cancer survivors. If detected early however, lymphoedema can be treated and managed fairly easily. Testing will be performed using ImpediMed's non-invasive L-Dex device which is sensitive enough to detect lymphoedema before it is visible. The target population will include newly-diagnosed patients at the Mercy Breast Care Center, and breast cancer patients of other surgeons in our region. We have made L-Dex testing our new standard of care and want other women to benefit from this technology," Dr. Schonholz added.

ImpediMed CEO, Mr Greg Brown said, "We wish to offer our congratulations to Dr. Schonholz on both this prestigious grant and his commitment to the pre-emptive care of patients to aid in the prevention of lymphoedema. For such a well recognized activist group like the Komen Foundation to identify the importance of Lymphoedema prevention is an important step in changing medical practice. Patient power cannot be underestimated in how it can help drive change from reactive care to pre-emptive care

models. Dr. Schonholz has been a strong supporter and early adopter of L-Dex technology in facilitating pre-emptive care. His experience in protecting his patient's quality of life from the devastation of lymphoedema over the last year has surely played a large part in his drive to apply for this Komen grant," Mr Brown commented.

Susan G. Komen for the Cure® is the global leader of the breast cancer movement, having invested nearly \$1.5 billion since its inception in 1982. As the world's largest grassroots network of breast cancer survivors and activists, Komen works to save lives, empower people, ensure quality care for all and energize science to find the cures. Komen is the largest source of non-profit funds dedicated to the fight against breast cancer in the world.

ENDS

For further information contact:

Greg Brown
ImpediMed CEO
T: 61-7-3860-3700
Mobile/Cell: +61408281127



L-Dex® is a trademark of ImpediMed Limited.

“ L-Dex® values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity”.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.

For more information, visit. www.impedimed.com.